Physician profile
Saba Khan
NPI 1376856187
$2,764.94
in general payments reported to CMS, 2019-2025
28 companies · $863 in 2025
The $863 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $56.41 · 2023: $343 · 2024: $1,117 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.65 | 2021-2025 | |
| Novo Nordisk INC | $437.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $229.76 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $179.24 | 2023-2024 | |
| Exact Sciences Corporation | $174.24 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $170.77 | 2024-2025 | |
| Alkermes, INC. | $149.03 | 2025 | Vivitrol |
| Indivior INC. | $62.86 | 2024-2025 | Sublocade, Perseris |
| Corium, LLC | $62.24 | 2023 | Azstarys |
| Viiv Healthcare Company | $62.22 | 2024 | Apretude |
| Abbott Laboratories | $61.96 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $56.26 | 2025 | Airsupra |
| Inspire Medical Systems, INC. | $48.10 | 2025 | Inspire |
| Corcept Therapeutics | $46.93 | 2025 | Korlym |
| Noven Therapeutics, LLC | $46.44 | 2025 | Xelstrym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $45.08 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $44.90 | 2023-2024 | |
| Hologic Sales and Service, LLC | $41.72 | 2023-2024 | Aptima |
| Dexcom, INC. | $39.65 | 2025 | Dexcom G6 Transmitter |
| Tris Pharma INC | $38.71 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $38.37 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $21.92 | 2025 | Gardasil 9, Capvaxive |
| Mayne Pharma Commercial LLC | $21.78 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.36 | 2024 | Rexulti |
| Coopersurgical, INC. | $18.33 | 2024 | Paragard T 380a |
| Ironshore Pharmaceuticals INC. | $17.26 | 2023 | Jornay Pm |
| Neos Therapeutics, Lp | $16.61 | 2023 | Adzenys Xr-Odt |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.